High mobility group box 1-mediated autophagy promotes neuroblastoma cell chemoresistance

Li Wang1, Huiping Zhang1, Min Sun1

  • 1Department of Neonatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China.

Oncology Reports
|September 24, 2015
PubMed

Insights

High mobility group box 1 (HMGB1) drives chemoresistance in neuroblastoma (NB) by promoting autophagy. Inhibiting HMGB1 may improve NB treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Neuroblastoma (NB) is a common childhood cancer with poor survival due to multidrug resistance.
  • High mobility group box 1 (HMGB1) is implicated in chemoresistance via autophagy in other cancers, but its role in NB is unclear.

Purpose of the Study:

  • To investigate the role of HMGB1 in chemoresistance and tumorigenesis in neuroblastoma.
  • To elucidate the molecular mechanism of HMGB1-mediated autophagy in NB.

Main Methods:

  • Human NB cells were treated with anticancer agents (doxorubicin, cisplatin, etoposide).
  • HMGB1 expression, translocation, and autophagic activity were assessed.
  • RNA interference was used to knockdown HMGB1.
  • Cell proliferation, invasion, and oxidative stress were evaluated.

Main Results:

  • Anticancer agents upregulated HMGB1, promoted its cytosolic translocation, and increased autophagy in NB cells.
  • HMGB1 knockdown restored chemosensitivity in NB cells.
  • HMGB1 enhanced NB cell proliferation and invasion by inducing Beclin-1-mediated autophagy.
  • HMGB1 facilitated autophagic progression and reduced doxorubicin-induced oxidative stress.

Conclusions:

  • HMGB1 is a critical regulator of autophagy in neuroblastoma, contributing to chemoresistance and tumorigenesis.
  • HMGB1 represents a potential therapeutic target for enhancing neuroblastoma treatment efficacy.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K